CLLS

Cellectis
CLLS

$2.30

10.24%

Market Cap: 230M

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Employees: 216

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

0.04% more ownership

Funds ownership: 13.68% [Q4 2023] → 13.73% (+0.04%) [Q1 2024]

12% less funds holding

Funds holding: 34 [Q4 2023] → 30 (-4) [Q1 2024]

14% less capital invested

Capital invested by funds: $30.2M [Q4 2023] → $26.1M (-$4.14M) [Q1 2024]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

79% less call options, than puts

Call options by funds: $17K | Put options by funds: $82K

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6

161%

upside

Avg. target

$8

248%

upside

High target

$10

335%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Hartaj Singh	335%upside $10	Outperform Maintained	12 Jun 2024
JMP Securities Silvan Tuerkcan	161%upside $6	Market Outperform Reiterated	31 May 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CLLS published over the past 30 days

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug (ODD) and Rare Pediatric Disease Designation (RPDD) Status to UCART22 product candidate for the treatment of Acute Lymphoblastic Leukemia (ALL).

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Zacks Investment Research

Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

Cellectis (CLLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing.

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Zacks Investment Research

Cellectis (CLLS) Upgraded to Buy: Here's Why

Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cellectis (CLLS) Upgraded to Buy: Here's Why

Zacks Investment Research

After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)

The heavy selling pressure might have exhausted for Cellectis (CLLS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease.

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the European Commission (EC) has granted an Orphan Drug Designation (ODD) to its product candidate UCART22, for the treatment of Acute Lymphoblastic Leukemia (ALL).

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

Cellectis S.A. (NASDAQ:CLLS ) Q1 2024 Earnings Conference Call May 29, 2024 8:00 AM ET Company Participants Arthur Stril - Interim-CFO André Choulika - CEO Mark Frattini - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dev Prasad - Jefferies Salveen Richter - Goldman Sachs Jack Allen - Baird Luisa Morgado - Van Lanschot Kempen Kuan-Hung Lin - Wells Fargo Operator Good morning, everyone, and welcome to the Cellectis First Quarter 2024 Earnings Call.

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032. Data update from phase 1/2 NATHALI-01 study, using UCART20x22 for the treatment of patients with B-cell non-Hodgkin lymphoma, expected by the end of 2024.

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

See News Rankings